The chemical class termed ISG20 Activators constitutes a broad spectrum of compounds strategically designed to modulate the activity of the ISG20 protein, an enzyme encoded by the ISG20 gene. These activators employ diverse mechanisms to exert their influence on ISG20, ranging from direct interactions with nuclear receptors to the intricate orchestration of cellular signaling pathways. In addition, activators bind to nuclear receptors, thereby initiating a cascade of events that culminate in the heightened transcription of the ISG20 gene. This transcriptional upregulation leads to an increased abundance of ISG20 protein, subsequently enhancing its enzymatic functions. The specificity of activators in targeting nuclear receptors highlights the precision with which they can manipulate gene expression to modulate ISG20 activity.
Furthermore, ISG20 activators delve into the realm of cellular signaling pathways to achieve their regulatory effects. For instance, Interferon-beta, another key component of this chemical class, activates ISG20 by initiating a signaling cascade. This cascade, triggered by the binding of Interferon-beta to its cognate receptors, sets off a series of events culminating in the upregulation of ISG20 expression. TLR3 agonists, including Poly I:C, engage Toll-like receptor 3, a crucial component of innate immunity, to activate ISG20 expression. The selective engagement of cellular receptors by ISG20 activators underscores the intricacies of their molecular interactions and the deliberate targeting of specific cellular pathways to achieve modulation of ISG20 expression and activity. Notably, JAK inhibitors within this chemical class exhibit a paradoxical effect on ISG20 activation. By inhibiting Janus kinases (JAKs), these compounds relieve negative feedback mechanisms, allowing for sustained JAK-STAT signaling. This sustained signaling, in turn, leads to increased ISG20 expression, showcasing the nuanced ways in which ISG20 activators can exploit intricate cellular feedback loops for their regulatory effects.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid can activate ISG20 by binding to its nuclear receptors, promoting the transcription of genes involved in ISG20 expression. | ||||||
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $663.00 | 2 | |
Poly I:C activates ISG20 through Toll-like receptor 3 (TLR3) signaling, triggering a downstream pathway that upregulates ISG20 gene expression. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $156.00 $339.00 | 59 | |
Paradoxically, inhibiting JAK can activate ISG20 by relieving negative feedback, allowing sustained JAK-STAT signaling, and increased ISG20 expression. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
TLR3 agonist activates ISG20 by engaging Toll-like receptor 3, initiating a signaling cascade that leads to increased ISG20 expression. | ||||||
Pimozide | 2062-78-4 | sc-203662 | 100 mg | $104.00 | 3 | |
HDAC inhibitor activates ISG20 by promoting histone acetylation, facilitating open chromatin conformation and enhancing ISG20 gene expression. | ||||||
GSK 2334470 | 1227911-45-6 | sc-364501 sc-364501A | 10 mg 50 mg | $199.00 $1165.00 | 1 | |
Inhibition of PKR can activate ISG20 by preventing PKR-mediated inhibition of translation, allowing increased synthesis of ISG20 protein. | ||||||